In addition, PSMA PET identified subgroups with discordant findings for EAU BCR risk label versus PET stage: 30% of post-RP EAU BCR high-risk patients had undetectable disease, whereas 24% of low-risk patients had metastatic disease, including 11% with bone metastases and 6% with visceral metastases. This evidence concerns the gene FOLH1 and metastatic neoplasm.